DK0431327T4 - Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter - Google Patents

Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter

Info

Publication number
DK0431327T4
DK0431327T4 DK90121189T DK90121189T DK0431327T4 DK 0431327 T4 DK0431327 T4 DK 0431327T4 DK 90121189 T DK90121189 T DK 90121189T DK 90121189 T DK90121189 T DK 90121189T DK 0431327 T4 DK0431327 T4 DK 0431327T4
Authority
DK
Denmark
Prior art keywords
lymphocytes
cytotoxic
specific induction
synthetic vaccine
killer
Prior art date
Application number
DK90121189T
Other languages
English (en)
Other versions
DK0431327T3 (da
Inventor
Guenther Jung
Hans-Georg Rammensee
Karl Deres
Karl-Heinz Wiesmueller
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6393249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0431327(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of DK0431327T3 publication Critical patent/DK0431327T3/da
Application granted granted Critical
Publication of DK0431327T4 publication Critical patent/DK0431327T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK90121189T 1989-11-10 1990-11-06 Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter DK0431327T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3937412A DE3937412A1 (de) 1989-11-10 1989-11-10 Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten

Publications (2)

Publication Number Publication Date
DK0431327T3 DK0431327T3 (da) 1996-08-12
DK0431327T4 true DK0431327T4 (da) 2001-06-18

Family

ID=6393249

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90121189T DK0431327T4 (da) 1989-11-10 1990-11-06 Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter

Country Status (9)

Country Link
EP (1) EP0431327B2 (da)
JP (1) JP3057748B2 (da)
AT (1) ATE137118T1 (da)
DE (2) DE3937412A1 (da)
DK (1) DK0431327T4 (da)
ES (1) ES2087111T5 (da)
GR (1) GR3019859T3 (da)
IE (1) IE74899B1 (da)
PT (1) PT95824B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
CA2081952A1 (en) * 1991-11-08 1993-05-09 John J. Donnelly Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
EP0547681A2 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a lipopeptide
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
BR9709993A (pt) 1996-06-25 1999-08-10 Stichting Inst Dierhouderij Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
AU2011232421B2 (en) * 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
NL2007536C2 (en) * 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401173A1 (fr) * 1977-06-27 1979-03-23 Roussel Uclaf Nouveaux steroides, leur procede de preparation et leur application dans la synthese de steroides marques au tritium
DE3683688D1 (de) * 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
DE3813821A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
WO1989002277A2 (en) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用

Also Published As

Publication number Publication date
ES2087111T3 (es) 1996-07-16
JP3057748B2 (ja) 2000-07-04
ES2087111T5 (es) 2001-06-16
JPH0454131A (ja) 1992-02-21
PT95824A (pt) 1991-09-13
EP0431327B1 (de) 1996-04-24
DK0431327T3 (da) 1996-08-12
EP0431327B2 (de) 2001-04-04
GR3019859T3 (en) 1996-08-31
PT95824B (pt) 2001-04-30
DE59010300D1 (de) 1996-05-30
IE904051A1 (en) 1991-05-22
EP0431327A1 (de) 1991-06-12
DE3937412A1 (de) 1991-05-16
IE74899B1 (en) 1997-08-13
ATE137118T1 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
IL102687A (en) Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0431327T3 (da) Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter
EP0523395A3 (da)
DE69840383D1 (de) Ctl epitope des epstein-barr virus
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
EP0468527A3 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
EP1630229A3 (en) Melanoma antigens
CA2261989A1 (en) Recombinant pox virus for immunization against tumor-associated antigens
EP0429477A4 (en) Synthetic vaccine against aids virus
EP0428596A4 (en) Novel infectious bursal disease virus
FI881418A7 (fi) Synteettiset peptidiantigeenit HIV-1 -infektion toteamiseksi.
DK388384A (da) Monoklone antistoffer med specifitet for membran-associerede antigener, deres fremstilling og anvendelse
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK0626452T3 (da) Vaccine mod infektion af Streptococcus suis
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DK322287A (da) Mod infektioner af pseudomonas aeruginosa virksomme praeparater og fremgangsmaade til fremstilling deraf
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
EP0906335A4 (en) Ebv ctl epitopes
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
CA2107329A1 (en) Anti-Human Immunodeficiency Virus Recombinant Antibodies
ZA888580B (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine